154 related articles for article (PubMed ID: 20372121)
1. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.
Trentacosti AM; He R; Burke LB; Griebel D; Kennedy DL
Am J Gastroenterol; 2010 Apr; 105(4):731-5. PubMed ID: 20372121
[TBL] [Abstract][Full Text] [Related]
2. [How can an effective drug to treat irritable bowel syndrome be successfully developed?].
Duracinsky M; Chassany O
Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S26-34. PubMed ID: 19303535
[TBL] [Abstract][Full Text] [Related]
3. Analyzing the content of outcome measures in clinical trials on irritable bowel syndrome using the international classification of functioning, disability and health as a reference.
Schönrich S; Brockow T; Franke T; Dembski R; Resch KL; Cieza A
Rehabilitation (Stuttg); 2006 Jun; 45(3):172-80. PubMed ID: 16755436
[TBL] [Abstract][Full Text] [Related]
4. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
5. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.
Mangel AW; Fehnel SE
Neurogastroenterol Motil; 2008 Oct; 20(10):1086-93. PubMed ID: 18826559
[TBL] [Abstract][Full Text] [Related]
6. Review article: probiotics and prebiotics in irritable bowel syndrome.
Spiller R
Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
[TBL] [Abstract][Full Text] [Related]
7. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
Camilleri M
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
[TBL] [Abstract][Full Text] [Related]
8. End points in irritable bowel syndrome.
Mangel AW; Fehnel SE
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
[No Abstract] [Full Text] [Related]
9. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome.
Ringel Y; Ringel-Kulka T
J Clin Gastroenterol; 2011 Nov; 45 Suppl():S145-8. PubMed ID: 21992954
[TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
11. Irritable bowel syndrome - The role of complementary medicines in treatment.
Pirotta M
Aust Fam Physician; 2009 Dec; 38(12):966-8. PubMed ID: 20369148
[TBL] [Abstract][Full Text] [Related]
12. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.
Quigley EM; Flourie B
Neurogastroenterol Motil; 2007 Mar; 19(3):166-72. PubMed ID: 17300285
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F; Talley NJ
Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
[TBL] [Abstract][Full Text] [Related]
14. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.
Bittner AC; Croffut RM; Stranahan MC
Clin Ther; 2005 Jun; 27(6):755-61. PubMed ID: 16117982
[TBL] [Abstract][Full Text] [Related]
15. Hypnosis for irritable bowel syndrome: the quest for the mechanism of action.
Simrén M
Int J Clin Exp Hypn; 2006 Jan; 54(1):65-84. PubMed ID: 16316884
[TBL] [Abstract][Full Text] [Related]
16. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
Corsetti M; Tack J
Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome.
Boyce PM; Talley NJ; Balaam B; Koloski NA; Truman G
Am J Gastroenterol; 2003 Oct; 98(10):2209-18. PubMed ID: 14572570
[TBL] [Abstract][Full Text] [Related]
18. Multidimensionality of symptom complexes in irritable bowel syndrome and other functional gastrointestinal disorders.
Alpers DH
J Psychosom Res; 2008 Jun; 64(6):567-72. PubMed ID: 18501256
[TBL] [Abstract][Full Text] [Related]
19. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.
Grover M; Herfarth H; Drossman DA
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):48-53. PubMed ID: 18848909
[TBL] [Abstract][Full Text] [Related]
20. Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues.
Cuomo R; Savarese MF; Gargano R
Dig Dis; 2007; 25(3):241-4. PubMed ID: 17827948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
